OXOTREMORINE
- CAS No.
- 70-22-4
- Chemical Name:
- OXOTREMORINE
- Synonyms
- oxotremorin;OXOTREMORINE;2’-oxopyrrolidino-1-pyrrolidino-4-butyne;1-(4-pyrrolidin-1-ylbut-2-ynyl)-2-pyrrolidone;1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinon;1-[4-(1-PYRROLIDINYL)-2-BUTYNYL]-2-PYRROLIDINONE;1-(4-(pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one;1-[4-(Pyrrolidin-1-yl)-2-butynyl]pyrrolidin-2-one;1-(4-(Pyrrolidin-1-yl)but-2-yn-1-yl)pyrrolidin-2-one;1-(2-Oxopyrrolidin-1-yl)-4-(pyrrolidin-1-yl)-2-butyne
- CBNumber:
- CB4133678
- Molecular Formula:
- C12H18N2O
- Molecular Weight:
- 206.28
- MDL Number:
- MFCD00003200
- MOL File:
- 70-22-4.mol
| Melting point | <25 °C |
|---|---|
| Boiling point | 124 °C0.1 mm Hg(lit.) |
| Density | 1 g/mL at 25 °C(lit.) |
| refractive index |
n |
| Flash point | 113 °C |
| storage temp. | 2-8°C |
| solubility | H2O: 50 mg/mL |
| form | liquid |
| pka | 8.29±0.20(Predicted) |
| color | clear, light yellow |
| Merck | 13,7020 |
| FDA UNII | 5RY0UWH1JL |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS05,GHS06 |
|---|---|
| Signal word | Danger |
| Hazard statements | H300-H314 |
| Precautionary statements | P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P280-P301+P330+P331-P303+P361+P353-P363-P304+P340-P310-P321-P305+P351+P338-P405-P501 |
| Hazard Codes | T+,C |
| Risk Statements | 28-34 |
| Safety Statements | 26-36/37/39-45 |
| RIDADR | UN 2810 6.1/PG 1 |
| WGK Germany | 3 |
| RTECS | UY5950100 |
| F | 10-23 |
| HazardClass | 6.1(a) |
| PackingGroup | I |
| Toxicity | LD50 ipr-rat: 4400 mg/kg TXAPA9 14,67,69 |
OXOTREMORINE price
OXOTREMORINE Chemical Properties,Uses,Production
Definition
ChEBI: Oxotremorine is a N-alkylpyrrolidine.
General Description
Oxotremorine [1-(-pyrrolidono)-4-pyrrolidino-2-butyne] has been regarded as a CNS muscarinicstimulant. Its action on the brain produces tremors inexperimental animals. It increases ACh brain levels in ratsup to 40% and has been studied as a drug in the treatment ofAlzheimer disease. Although earlier studies suggested thatthis approach of elevating levels of ACh to treat Alzheimerdisease is useful, this belief was highly disputed by manyresearchers.
Clinical Use
Nevertheless, oxotremorine, as a cholinergicagonist, facilitates memory storage. These findings haveserved as important leads in the development of agents usefulin treating Alzheimer disease. Although it possessesgroups that do not occur in other highly active muscarinicagents, oxotremorine’s trans conformation shows that distancesbetween possible active centers correspond with (+)-muscarine.
Safety Profile
Poison by ingestion and intraperitoneal routes. Moderately toxic by intravenous route. When heated to decomposition it emits toxic fumes of NOx.
OXOTREMORINE Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Nanjing Bicbiotechnology Co., Ltd | +86-2552131256 +86-18251840740 | sales@bicbiotech.com | China | 6000 | 58 |
| 3B Pharmachem (Wuhan) International Co.,Ltd. | 821-50328103-801 18930552037 | 3bsc@sina.com | China | 15848 | 69 |
| Shaanxi DIDU pharmaceutical and Chemical Co., Ltd | 15229059051 | 1027@dideu.com | China | 9926 | 58 |
| Nanjing Bic Biotechnology Co., Ltd | 025-58906079 | sales@bicbiotech.com | China | 6128 | 58 |